# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Omar Nokta maintains Frontline (NYSE:FRO) with a Buy and maintains $30 price target.
Frontline reported Q2 FY24 revenue of $607.5 million, beating consensus. Net operating income improved, but adjusted EPS missed...
Frontline (NYSE:FRO) reported quarterly earnings of $0.62 per share which missed the analyst consensus estimate of $0.67 by 7.4...
Evercore ISI Group analyst Jonathan Chappell maintains Frontline (NYSE:FRO) with a Outperform and lowers the price target fr...
Jefferies analyst Omar Nokta maintains Frontline (NYSE:FRO) with a Buy and maintains $30 price target.
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...